Relay Therapeutics (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 1,459 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 1,459 shares of the stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $18.61, for a total transaction of $27,151.99. Following the sale, the chief financial officer directly owned 158,285 shares in the company, valued at approximately $2,945,683.85. This represents a 0.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Thomas Catinazzo also recently made the following trade(s):

• On Monday, July 6th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The stock was sold at an average price of $18.69, for a total transaction of $331,130.73.
• On Monday, June 22nd, Thomas Catinazzo sold 187,163 shares of Relay Therapeutics stock. The stock was sold at an average price of $16.97, for a total transaction of $3,176,156.11.
• On Thursday, May 14th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The shares were sold at an average price of $12.86, for a total transaction of $227,840.62.

Relay Therapeutics Price Performance

Shares of Relay Therapeutics stock opened at $19.45 on Friday. The firm has a 50 day simple moving average of $17.06 and a 200 day simple moving average of $13.03. Relay Therapeutics, Inc. has a fifty-two week low of $3.03 and a fifty-two week high of $20.79. The firm has a market cap of $3.73 billion, a P/E ratio of -12.39 and a beta of 1.67.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $5.58 million. On average, sell-side analysts expect that Relay Therapeutics, Inc. will post -1.57 EPS for the current year.

Institutional Investors Weigh In On Relay Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Torren Management LLC acquired a new position in Relay Therapeutics in the fourth quarter valued at about $30,000. KBC Group NV acquired a new position in shares of Relay Therapeutics during the 1st quarter worth about $34,000. Smartleaf Asset Management LLC grew its position in shares of Relay Therapeutics by 288.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock worth $37,000 after buying an additional 3,287 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Relay Therapeutics in the 4th quarter valued at approximately $46,000. Finally, Captrust Financial Advisors acquired a new stake in shares of Relay Therapeutics in the 2nd quarter valued at approximately $49,000. Institutional investors own 96.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Monday, July 6th. Wells Fargo & Company upped their target price on shares of Relay Therapeutics from $17.00 to $21.00 and gave the company an “overweight” rating in a research report on Tuesday, April 28th. UBS Group set a $26.00 target price on shares of Relay Therapeutics in a research note on Tuesday, May 19th. Citigroup reaffirmed an “outperform” rating on shares of Relay Therapeutics in a research note on Wednesday, May 20th. Finally, HC Wainwright lifted their price target on shares of Relay Therapeutics from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.92.

Trending Headlines about Relay Therapeutics

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Analysts at Zacks said Relay Therapeutics may beat consensus earnings expectations in its upcoming report, potentially providing a near-term catalyst for RLAY. The preview cites favorable expectations but does not represent an actual earnings result. Relay Therapeutics Expected to Beat Earnings Estimates
• Positive Sentiment: Relay’s breast cancer program has helped revitalize investor interest in the clinical-stage biotechnology company, although the opportunity faces intense competition from other drug developers. Relay Therapeutics Revitalized by Breast Cancer Program
• Neutral Sentiment: Relay Therapeutics will release second-quarter 2026 financial results and corporate highlights after the market closes on August 6. Investors will likely focus on pipeline progress, cash resources and guidance for upcoming clinical development. Relay Therapeutics to Announce Second-Quarter Results
• Neutral Sentiment: Three insiders, including CFO Thomas Catinazzo, sold a combined 4,444 shares at an average price of $18.61. The filings state the sales were made to cover tax withholding obligations tied to vested equity awards, and each insider retained a substantial ownership position, reducing the bearish significance.
• Negative Sentiment: The company remains a clinical-stage biotechnology firm, so its valuation depends heavily on successful development and commercialization of its pipeline. Competitive pressure in breast cancer could limit the potential upside and increase execution risk.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.